How diet and metabolism affect HIV-1 reservoirs in the body
Official title: The intersection of diet, cell metabolic state, and SIV reservoir transcription
Funded at Tulane University of Louisiana · NIH-10904659 · Data updated 2026-11-12
This study is looking at how what you eat and your body's metabolism affect certain immune cells that can hide the HIV virus, with the goal of finding better treatment options for people living with HIV, especially those who also have type 2 diabetes.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tulane University of Louisiana NIH-funded |
| Lab location | 1 site (New Orleans, United States) |
| Project start | August 10, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $212,215 |
| NIH project number | 5R21AI174901-02 |
| Project ID | NIH-10904659 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals living with HIV-1, particularly those who also have type 2 diabetes or other metabolic conditions.
✕Less likely to help
Patients who are not living with HIV-1 or do not have related metabolic conditions may not benefit from this research.
What this research studies
This research investigates the relationship between diet, metabolic states, and the behavior of HIV-1 reservoirs in the body, specifically focusing on resting memory CD4 T cells. The study aims to understand how these cells, which can harbor the virus, respond to dietary factors and insulin signaling. By exploring the effects of latency reversal agents on these reservoirs, the research seeks to identify more effective treatment strategies for individuals living with HIV-1, particularly those with co-existing conditions like type 2 diabetes. The approach includes both clinical and pre-clinical trials to assess the impact of these factors on HIV-1 transcriptional activity.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for reducing HIV-1 reservoirs, potentially paving the way for a functional cure.
How similar studies have gone: Previous studies have shown some success with latency reversal agents in small cohorts, but this research aims to broaden the understanding by including a more diverse patient population.
Where this research is happening
-
Tulane University of Louisiana
New Orleans, United States Active
Researchers
- Principal investigator: Mudd, Joseph Christopher — Tulane University of Louisiana
- Study coordinator: Mudd, Joseph Christopher
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.